Skip to main content

Table 2 Numbers, amyloid PET positive percentage, and plasma biomarkers in APOE ε4 carriers and non-carriers

From: Plasma amyloid assay as a pre-screening tool for amyloid positron emission tomography imaging in early stage Alzheimer’s disease

APOE genotype ε4 carriers ε4 non-carriers
ε4 carriers (ε2ε4, ε3ε4, ε4ε4) All ε4 non-carriers (ε2ε2, ε2ε3, ε3ε3) ε4 carriers (ε2ε2, ε2ε3)
Amyloid PET+% 85.7% 26.3% 0
Plasma Aβ1–40 (pg/ml) 47.1 ± 7.2 50.9 ± 7.4 50.0 ± 8.5
Plasma Aβ1–42 (pg/ml) 17.9 ± 2.9 16.7 ± 2.9 16.5 ± 2.7
Plasma tau (pg/ml) 24.7 ± 9.9 19.3 ± 9.5* 18.8 ± 8.2
Plasma Aβ1–42/Aβ1–40 0.396 ± 0.117 0.343 ± 0.111 0.349 ± 0.126
Plasma Aβ1–42xtau (pg2/ml2) 468.2 ± 262.2 348.6 ± 242.1 331.0 ± 208.6
  1. Abbreviations: Amyloid β, PET positron emission tomography
  2. *P value < 0.05: ε4 carriers vs ε4 non-carriers